A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”

Benjamin Z. Leder, Bart Clarke, Elizabeth Shane, Sundeep Khosla, Douglas P. Kiel

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled “Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention” designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on “gaps” in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment.

Original languageEnglish (US)
JournalJournal of Bone and Mineral Research
DOIs
StateAccepted/In press - Jan 1 2019

Keywords

  • FRACTURE PREVENTION
  • OSTEOPOROSIS
  • OSTEOPOROSIS DRUG THERAPY

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report “Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention”'. Together they form a unique fingerprint.

  • Cite this